Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses

Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses

Alemtuzumab (anti-CD52 mAb) leads to a long-lasting disease activity suppression in patients with relapsing forms of multiple sclerosis (MS). In this study, we examined the change of the immune cell repertoire and the cellular reactivity after treatment with alemtuzumab. We analyzed the number of IF...

Full description

Bibliographic Details
Main Authors: Clara Hilger, Christine Riedhammer, Evelyn Orsó, Robert Weissert
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Immunology
Subjects:
immunotherapy
mechanism of action
multiple sclerosis
alemtuzumab
autoantigen
T cell
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.563645/full

Similar Items

Similar Items